Multiple Myeloma – VJRegenMed

KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma

Anya Kerkache — Thu, 09 Mar 2023 11:31:45 +0000

In this video, Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the results of the KarMMa-3 study (NCT03651128), a Phase III trial comparing idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple class–exposed relapsed/refractory (R/R) multiple myeloma. The study reported a significant benefit for ide-cel in terms of complete remission (CR) rate and progression-free survival (PFS) across all risk categories. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, briefly discusses CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA, including agents targeting GPRC5D, CD38 and SLAMF7. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The importance of managing hematologic toxicity associated with CAR-T therapy

Anya Kerkache — Wed, 08 Mar 2023 10:35:17 +0000

In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, comments on the importance of improving methods of assessing and managing hematologic toxicity associated with the use of CAR-T therapy. Prof. Subklewe also shares some insights into the novel CAR-HEMATOTOX risk stratification tool being evaluated in patients treated with CAR-T therapy for various hematological malignancies. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Phase I study of CC-98633 in R/R multiple myeloma

Anya Kerkache — Thu, 26 Jan 2023 12:11:26 +0000

In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some results from a Phase I study evaluating CC-98633, a next-generation BCMA-targeting CAR-T cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma (NCT04394650). Dr Costa first highlights the NEX-T manufacturing process used to develop this agent, and then discusses the activity and safety of this agent as demonstrated in the study. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Targeting neoantigens in multiple myeloma with CAR T-cell

Simon Ng — Tue, 12 Apr 2022 11:18:09 +0000

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies such as ciltacabtagene autoleucel and idecabtagene vicleucel have made a positive impact on the treatment landscape of multiple myeloma. However, tumor heterogeneity, antigen escape and an immunosuppressive tumor microenvironment are barriers CAR T-cell therapies currently face. Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, describes research on neoantigens and its benefits. As neoantigens are only found in the tumor, off-target effects such as B-cell aplasia and cytokine release syndrome (CRS) are reduced. Utilizing alternative targets such as SLAMF7 and CD38, as well as bispecific CAR T-cells represent novel strategies to optimize immunotherapies for multiple myeloma. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Updates in cell and gene therapy approvals

Simon Ng — Wed, 02 Mar 2022 11:58:18 +0000

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, describes recent approvals and developments within the advanced therapy space, including the FDA approval of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory multiple myeloma. Dr Levine additionally highlights developments in tumor-infiltrating lymphocytes (TILs), as well the need to focus on Chemistry, Manufacturing, and Control (CMC) standards within the regulatory process. This interview took place at Advanced Therapies Week 2022.

Exciting advances in CAR-T and TCR research

admin_vjr_user — Tue, 24 Aug 2021 13:22:11 +0000

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, offers some of his highlights from the CAR-TCR Summit Europe 2021. He describes CYAD-211, a short hairpin RNA (shRNA)-based B-cell maturation antigen (BCMA)-targeting allogeneic chimeric antigen receptor (CAR) T candidate, which is being investigated in ongoing clinical trials for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM). He also discusses exciting developments presented at the meeting, included advances in the understanding of the mechanisms of action of CD19-targeting CAR T-cell therapies, as well as advances in T-cell receptor (TCR) platforms under investigation. This interview took place during the CAR-TCR Summit Europe 2021.

Challenges of CAR T-cell therapy for AML: is CD38 the answer?

admin_vjr_user — Thu, 05 Aug 2021 11:33:45 +0000

Lei Yu, MD, PhD, Shanghai Unicar-Therapy Biomed-Pharmaceutical Technology Co. Ltd, China, explains that chimeric antigen receptor (CAR) T-cell therapies have been effective in treating hematologic B-cell malignancies, as they contain several antigens exclusive to the B-cell lineage, such as CD19, that can be targeted without causing significant harm to the patient. A key challenge facing CAR T-cell therapy for AML, however, is the identification of AML-specific target antigens, since myeloid antigens are often co-expressed on healthy bone marrow cells, which when targeted with CAR T-cells can cause fatal myeloablation. CD38 is being investigated as a target antigen for AML CAR T-cell therapy, as it is expressed on AML cells but not healthy bone marrow cells. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Improving education in cell therapy

admin_vjr_user — Fri, 30 Apr 2021 10:09:52 +0000

Emanuele Ostuni, Head of Europe, Cell and Gene Therapy, Novartis Oncology, East Hanover, NJ, discusses the importance of educating patients on novel therapeutic modalities being developed for hematological malignancies such as lymphoma, myeloma and leukemia in order to give patients a better understanding of their treatment options. He also points out that improved education for healthcare professionals on novel treatment options such as CAR-T therapy is needed in order for them to be able to make more informed decisions for their patients. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The European cell & gene therapy landscape

admin_vjr_user — Sat, 10 Apr 2021 10:58:01 +0000

Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., provides an overview of the cell and gene therapy sector in Europe. In 2021, there are currently five approved gene therapies and six cell therapies on market in Europe but it is predicted that by 2025, the European Medicines Agency (EMA) will approve 10-20 new cell and gene therapies each year. It is therefore important that current challenges surrounding policy, regulation and reimbursement are addressed in the near future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.